=== SEC Form 4 — Statement of Changes in Beneficial Ownership ===
Document Type: 4
Period of Report: 2026-01-07
10b5-1 Pre-arranged Plan: Yes
--- Issuer ---
Name: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
--- Reporting Owner ---
Name: Bassler Bonnie L
CIK: 0001683607
Role: Director
--- Non-Derivative Transactions ---
[Transaction #1]
Security: Common Stock
Date: 2026-01-07 | Code: M (Exercise of derivative)
Shares: +1,500 | Price: $374.12
Total Value: $561,180.00
Shares Owned After: 3,203 | Ownership: D (Direct)
Footnotes:
[F1] Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025.
[Transaction #2]
Security: Common Stock
Date: 2026-01-07 | Code: S (Open market sale)
Shares: -1,500 | Price: $800.00
Total Value: $1,200,000.00
Shares Owned After: 1,703 | Ownership: D (Direct)
Footnotes:
[F1] Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025.
[F2] Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price.
--- Derivative Transactions ---
[Transaction #1]
Security: Non-Qualified Stock Option (right to buy)
Date: 2026-01-07 | Code: M (Exercise of derivative)
Shares: -1,500 | Price: $0.00
Exercisable: N/A | Expires: 2030-01-02
Shares Owned After: 2,861 | Ownership: D (Direct)
Footnotes:
[F1] Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025.
[F3] On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
--- Footnotes (Complete Index) ---
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025.
F2: Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price.
F3: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
--- Signature ---
/s/ /s/ Bonnie L. Bassler (2026-01-08)
